When, if ever, would you continue pembrolizumab for more than two years in metastatic or recurrent MSI-H endometrial cancer?

Would you continue pembrolizumab for more than two years in metastatic or recurrent MSI-H endometrial cancer assuming it is well tolerated and there is no evidence of disease progression?

• Yes, with continuous use
• No
• Only in the setting of clinical trial
• Yes, in a setting of different treatment regimens or at different times in the treatment course